Evogene Ltd., a biotechnology company, engages in developing various products for life science markets through the use of computational predictive biology platform in the United States, Israel, Germany, and internationally.
The last earnings update was 24 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Evogene. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Evogene's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Evogene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Evogene's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Evogene's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Evogene's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Evogene is high growth as no earnings estimate data is available.
Unable to determine if Evogene is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Evogene's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Ofer Haviv, CPA, has been the Chief Executive Officer and President of Evogene Limited since December 2004 and served as its Chief Financial Officer and Chief Operating Officer from January 2002 to 2004. Mr. Haviv serves as Chairman of Lavie Bio Ltd since September 11, 2019. Mr. Haviv served as Deputy Chief Financial Officer of Evogene Ltd. He served as Director of Finance and Treasurer for Compugen. He served as the Chief Financial Officer of Klei Zemmer, a national retail concern, where he was responsible for financial reporting, budgets and control. He has an extensive experience in global finance. He serves as a Director of Coronis NeuroSciences Ltd. He served as Observer of Kadimastem Ltd until June 8, 2017. Mr. Haviv holds a BA and an MA in Economics from the Tel Aviv University and is a Certified Public Accountant in Israel.
Ofer's compensation has been consistent with company performance over the past year, both up more than 20%.
Ofer's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Evogene management team is less than 2 years, this suggests a new team.
CEO & President
Executive Vice President of Technology
Chief Financial Officer
Chief Scientific Officer
Investor Relation & Public Relations Manager
VP of Legal Affairs & Company Secretary
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Evogene board of directors is about average.
Board of Directors
Independent Chairman of the Board
Chairman of Scientific Advisors
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Evogene Ltd., a biotechnology company, engages in developing various products for life science markets through the use of computational predictive biology platform in the United States, Israel, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, castor oil, and human microbiome-based therapeutics. The company operates through three segments: Evogene, Evofuel, and Biomica. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants and bio-pesticides. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced castor bean seeds to serve as a feedstock source for industrial uses. The Biomica segment discovers and develops human microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases. The company also provides medical cannabis products. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF, Corteva, Bayer, and ChemChina. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.